Citadel Advisors
BCYC

Citadel Advisors’s Bicycle Therapeutics BCYC Stock Holding History

Citadel Advisors’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.35M Buy
554,225
+177,140
+47% +$812K ﹤0.01% 6202
2026
Q1 		$1.75M Buy
377,085
+105,702
+39% +$604K ﹤0.01% 6374
2025
Q4 		$1.92M Buy
271,383
+82,356
+44% +$607K ﹤0.01% 5996
2025
Q3 		$1.46M Buy
189,027
+49,560
+36% +$374K ﹤0.01% 6717
2025
Q2 		$969K Buy
139,467
+9,397
+7% +$74.8K ﹤0.01% 7169
2025
Q1 		$1.1M Sell
130,070
-14,160
-10% -$167K ﹤0.01% 6744
2024
Q4 		$2.02M Buy
144,230
+41,481
+40% +$889K ﹤0.01% 5599
2024
Q3 		$2.33M Sell
102,749
-79,566
-44% -$1.84M ﹤0.01% 5250
2024
Q2 		$3.69M Buy
182,315
+122,875
+207% +$2.78M ﹤0.01% 4238
2024
Q1 		$1.48M Sell
59,440
-235,025
-80% -$4.99M ﹤0.01% 6110
2023
Q4 		$5.32M Buy
294,465
+158,768
+117% +$2.63M ﹤0.01% 3689
2023
Q3 		$2.73M Buy
135,697
+24,541
+22% +$561K ﹤0.01% 4658
2023
Q2 		$2.84M Buy
111,156
+43,956
+65% +$1.02M ﹤0.01% 4565
2023
Q1 		$1.43M Buy
67,200
+34,210
+104% +$858K ﹤0.01% 6011
2022
Q4 		$977K Sell
32,990
-15,414
-32% -$414K ﹤0.01% 6862
2022
Q3 		$1.13M Sell
48,404
-194,930
-80% -$4.64M ﹤0.01% 6728
2022
Q2 		$4.08M Buy
+243,334
New +$5.13M ﹤0.01% 4173
2022
Q1 		– Sell
-58,187
Closed -$2.72M – 13567
2021
Q4 		$3.54M Buy
58,187
+32,840
+130% +$1.81M ﹤0.01% 5001
2021
Q3 		$1.05M Buy
+25,347
New +$887K ﹤0.01% 8019
2021
Q1 		– Sell
-29,035
Closed -$521K – 13153
2020
Q4 		$521K Buy
+29,035
New +$561K ﹤0.01% 8074

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Citadel Advisors's BCYC Position: Q2 2026 in Review

Citadel Advisors increased its Bicycle Therapeutics (BCYC) stake by 47% in Q2 2026, buying an estimated $812K and bringing the position to 554,225 shares worth $2.35M. The position accounts for ﹤0.01% of the portfolio, ranked #6202.

Citadel Advisors first reported a position in BCYC in Q4 2020 and has held it in 20 quarters since. The position peaked at $5.32M in Q4 2023. 104 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

  • Citadel Advisors held 554,225 shares of Bicycle Therapeutics worth $2.35M as of Q2 2026.
  • Citadel Advisors bought 177,140 Bicycle Therapeutics shares in Q2 2026, an estimated $812K.
  • Bicycle Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #6202 holding.
  • Citadel Advisors first reported a position in Bicycle Therapeutics in Q4 2020 and has held it in 20 quarters since.
  • Citadel Advisors's Bicycle Therapeutics position peaked at $5.32M in Q4 2023.
  • 104 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.